ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$65.48 USD
+0.90 (1.39%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $65.49 +0.01 (0.02%) 4:54 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum C VGM
Brokerage Reports
0 items in cart
ANI Pharmaceuticals, Inc. [ANIP]
Reports for Purchase
Showing records 41 - 60 ( 88 total )
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q15 Recap - Messy Quarter, but Progress Underway
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Updated Model - Adjusting PT to Reflect More Conservative Environment
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Flecainide Could Add ~$0.20 to EPS Line in 2016+
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q14 Quick Take - Great Quarter, Guidance Looks Conservative
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Upping PT to $65; Upside from Methazolamide and Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q14 Recap - Higher Revenue and EPS Trajectory; PT to $55
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.